Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome

Olive, Kenneth P., Tuveson, David A., Ruhe, Zachary C., Yin, Bob, Willis, Nicholas A., Bronson, Roderick T., Crowley, Denise, Jacks, Tyler·2004·Cell

DOI 10.1016/j.cell.2004.11.004

Cited by (1,000)

Items 101–200 of 1,000

TP53: an oncogene in disguise
Soussi, T, Wiman, K G · 2015 · Cell Death & Differentiation
Mouse models for human lung cancer
Ralph Leo Johan Meuwissen, Anton J. M. Berns · 2005 · Genes & Development
A spatially and temporally restricted mouse model of soft tissue sarcoma
David G. Kirsch, Daniela M. Dinulescu, John B. Miller, Jan Grimm, Philip M. Santiago, Nathan P Young, G. Petur Nielsen, Bradley J. Quade, Christopher J. Chaber, Christian P Schultz et al. · 2007 · Nature Medicine
Tumor suppressor p53 and metabolism
Juan Liu, Cen Zhang, Wenwei Hu, Zhaohui Feng · 2018 · Journal of Molecular Cell Biology
A Translational View of the Molecular Pathogenesis of Lung Cancer
Mitsuo Sato, David S. Shames, Adi F. Gazdar, John Dorrance Minna · 2007 · Journal of Thoracic Oncology
Functional Inactivation of Endogenous MDM2 and CHIP by HSP90 Causes Aberrant Stabilization of Mutant p53 in Human Cancer Cells
Dun Li, Natalia D. Marchenko, Ramona Schulz‐Heddergott, Victoria Fischer, Talía Velasco-Hernández, Flaminia Talos, Ute Martha Moll · 2011 · Molecular Cancer Research
p63-Associated Disorders
Tuula Rinne, Hans G. Brunner, Hans van Bokhoven · 2007 · Cell Cycle
p53 Efficiently Suppresses Tumor Development in the Complete Absence of Its Cell-Cycle Inhibitory and Proapoptotic Effectors p21, Puma, and Noxa
Liz J. Valente, Daniel H.D. Gray, Ewa Malgorzata Michalak, Josefina Piñón Hofbauer, Alexander Egle, Clare L. Scott, Ana Janic, Andreas Strasser · 2013 · Cell Reports
The rebel angel: mutant p53 as the driving oncogene in breast cancer
Dawid Walerych, Marco Napoli, Licio Collavin, Giannino Del Sal · 2012 · Carcinogenesis
Regulation of the p53 response and its relationship to cancer
David W. Meek · 2015 · Biochemical Journal
MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner
Bond, Gareth L., Hirshfield, Kim M., Kirchhoff, Tomas, Alexe, Gabriella, Bond, Elisabeth E., Robins, Harlan, Bartel, Frank, Taubert, Helge, Wuerl, Peter, Hait, William et al. · 2006 · Cancer Research
Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy
Bryan W Miller, Jennifer P. Morton, Mark Pinese, Grazia Saturno, Nigel Balfour Jamieson, Ewan James McGhee, Paul Timpson, Joshua D.G. Leach, Lynn McGarry, Emma J. Shanks et al. · 2015 · EMBO Molecular Medicine
A Pin1/Mutant p53 Axis Promotes Aggressiveness in Breast Cancer
Javier E. Girardini, Marco Napoli, Silvano Piazza, Alessandra Rustighi, Carolina Marotta, Enrico Radaelli, Valeria Capaci, Lee B. Jordan, Philip Quinlan, Alastair Thompson et al. · 2011 · Cancer Cell
Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis
Walter G. Hanel, N D Marchenko, Suheng Xu, Stephen Yu, W Weng, Ute Martha Moll · 2013 · Cell Death and Differentiation
Mutant p53 in colon cancer
Mizuho Nakayama, Masanobu Oshima · 2018 · Journal of Molecular Cell Biology
The p53 network: cellular and systemic DNA damage responses in cancer and aging
Pavana Lakshmi Vaddavalli, Björn Schumacher · 2022 · Trends in Genetics
The microRNA-200 family regulates pancreatic beta cell survival in type 2 diabetes
Bengt‐Frederik Belgardt, Kashan Ahmed, Martina Spranger, Mathieu Latreille, Rémy Denzler, Nadiia Kondratiuk, Ferdinand von Meyenn, Felipe Nunez Villena, Karolin Herrmanns, Domenico Bosco et al. · 2015 · Nature Medicine
Deletions linked to TP53 loss drive cancer through p53-independent mechanisms
Yu Liu, Chong Chen, Zhengmin Xu, Claudio Scuoppo, Cory D. Rillahan, Jianjiong Gao, Barbara G. Spitzer, Benedikt Bosbach, Edward R. Kastenhuber, Timour Baslan et al. · 2016 · Nature
CAF hierarchy driven by pancreatic cancer cell p53-status creates a pro-metastatic and chemoresistant environment via perlecan
Vennin, Claire, Mélénec, Pauline, Rouet, Romain, Nobis, Max, Cazet, Aurélie S., Murphy, Kendelle J., Herrmann, David, Reed, Daniel A., Lucas, Morghan C., Warren, Sean C. et al. · 2019 · Nature Communications
p53 mutation heterogeneity in cancer
Thierry Soussi, Guillermina Lozano · 2005 · Biochemical and Biophysical Research Communications
Molecular Pathogenesis of Osteosarcoma
Maya Kansara, David Morgan Thomas · 2007 · DNA and Cell Biology
Tumor suppressor p53 and its mutants in cancer metabolism
Juan Liu, Cen Zhang, Wenwei Hu, Zhaohui Feng · 2013 · Cancer Letters
Mutant p53: an oncogenic transcription factor
Sabrina Strano, Stefania Dell’Orso, Silvia Di Agostino, Giulia Fontemaggi, Ada Sacchi, Giovanni Blandino · 2007 · Oncogene
Temporal Dissection of Tumorigenesis in Primary Cancers
Steffen Durinck, Christine Ho, Nicholas J. Wang, Wilson J. Liao, Lakshmi R. Jakkula, Eric A. Collisson, Jennifer Pons, Sai-Wing Chan, Ernest T. Lam, Catherine Chu et al. · 2011 · Cancer Discovery
Pancreatic cancer modeling using retrograde viral vector delivery and in vivo CRISPR/Cas9-mediated somatic genome editing
Shin‐Heng Chiou, Ian P. Winters, Jing Wang, Santiago Naranjo, Crissy Dudgeon, Fiona B. Tamburini, Brady Jennifer J, Dian Yang, Barbara M. Grüner, Chen-Hua Chuang et al. · 2015 · Genes & Development
P53 and Prognosis
Karen H. Vousden, Carol L. Prives · 2005 · Cell
Analysis of P53 mutations and their expression in 56 colorectal cancer cell lines
Liu, Ying, Bodmer, Walter F. · 2006 · Proceedings of the National Academy of Sciences
KRASG12D inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8+ T cells
Mahadevan, Krishnan K., McAndrews, Kathleen M., LeBleu, Valerie S., Yang, Sujuan, Lyu, Hengyu, Li, Bingrui, Sockwell, Amari M., Kirtley, Michelle L., Morse, Sami J., Moreno Diaz, Barbara A. et al. · 2023 · Cancer Cell
Smoking, p53 Mutation, and Lung Cancer
Gibbons, Don L., Byers, Lauren A., Kurie, Jonathan M. · 2014 · Molecular Cancer Research
InheritedTP53Mutations and the Li–Fraumeni Syndrome
Tanya Guha, David M. Malkin · 2017 · Cold Spring Harbor Perspectives in Medicine
Ultraviolet radiation accelerates BRAF-driven melanomagenesis by targeting TP53
Viros, Amaya, Sanchez-Laorden, Berta, Pedersen, Malin, Furney, Simon J., Rae, Joel, Hogan, Kate, Ejiama, Sarah, Girotti, Maria Romina, Cook, Martin, Dhomen, Nathalie et al. · 2014 · Nature
Mutant p53 in cancer therapy—the barrier or the path
Xiang Yu Zhou, Qian Hao, Hua Lu · 2018 · Journal of Molecular Cell Biology
Targeting Tumor Suppressor p53 for Cancer Therapy: Strategies, Challenges and Opportunities
Bo Hong, A. Pieter J. van den Heuvel, Varun V. Prabhu, Shengliang Zhang, Wafik S. El‐Deiry · 2014 · Current Drug Targets
Molecular Biology of Lung Cancer: Clinical Implications
Jill E. Larsen, John Dorrance Minna · 2011 · Clinics in Chest Medicine
The Use of Targeted Mouse Models for Preclinical Testing of Novel Cancer Therapeutics
Kenneth P. Olive, David Arthur Tuveson · 2006 · Clinical Cancer Research
Molecular genetics of osteosarcoma
Kirby Rickel, Fang Fang, Jianning Tao · 2016 · Bone
Ordered and deterministic cancer genome evolution after p53 loss
Baslan, Timour, Morris, John P., Zhao, Zhen, Reyes, Jose, Ho, Yu-Jui, Tsanov, Kaloyan M., Bermeo, Jonathan, Tian, Sha, Zhang, Sean, Askan, Gokce et al. · 2022 · Nature
KMT2D Deficiency Impairs Super-Enhancers to Confer a Glycolytic Vulnerability in Lung Cancer
Alam, Hunain, Tang, Ming, Maitituoheti, Mayinuer, Dhar, Shilpa S., Kumar, Manish, Han, Chae Young, Ambati, Chandrashekar R., Amin, Samir B., Gu, Bingnan, Chen, Tsai-Yu et al. · 2020 · Cancer Cell
Gain-of-Function Mutant p53 Promotes Cell Growth and Cancer Cell Metabolism via Inhibition of AMPK Activation
Ge Zhou, Jiping Wang, Mei Zhao, Tong‐Xin Xie, Noriaki Tanaka, Daisuke Sano, Ameeta A. Patel, Alexandra M. Ward, Vlad Constantin Sandulache, Samar A. Jasser et al. · 2014 · Molecular Cell
A Sleeping Beauty forward genetic screen identifies new genes and pathways driving osteosarcoma development and metastasis
Branden S. Moriarity, George Maxwell Otto, Eric P. Rahrmann, Susan K. Rathe, Natalie K. Wolf, Madison T. Weg, Luke A Manlove, Rebecca S. LaRue, Nuri A. Temiz, Sam D. Molyneux et al. · 2015 · Nature Genetics
Therapeutic Ablation of Gain-of-Function Mutant p53 in Colorectal Cancer Inhibits Stat3-Mediated Tumor Growth and Invasion
Ramona Schulz‐Heddergott, Nadine Stark, Shelley J. Edmunds, Jinyu Li, Lena‐Christin Conradi, Hanibal Bohnenberger, Fatih Ceteci, Florian R. Greten, Matthias Dobbelstein, Ute Martha Moll · 2018 · Cancer Cell
Cells of origin in osteosarcoma: Mesenchymal stem cells or osteoblast committed cells?
Mutsaers, Anthony J., Walkley, Carl R. · 2014 · Bone
A next-generation dual-recombinase system for time- and host-specific targeting of pancreatic cancer
Nina Schönhuber, Barbara Seidler, Kathleen Schuck, Christian Veltkamp, Christina Schachtler, Magdalena Zukowska, Stefan Eser, Thorsten B. Feyerabend, Mariel C. Paul, Philipp Eser et al. · 2014 · Nature Medicine
p53 alterations in human cancer: more questions than answers
Thierry Soussi · 2007 · Oncogene
Molecular basis of the Li-Fraumeni syndrome: an update from the French LFS families
Bougeard, G, Sesboüé, R, Baert-Desurmont, S, Vasseur, S, Martin, C, Tinat, J, Brugières, L, Chompret, A, Paillerets, B Bressac-de, Stoppa-Lyonnet, D et al. · 2008 · Journal of Medical Genetics
Deconstructing networks of p53-mediated tumor suppression in vivo
Alyssa M. Kaiser, Laura Donatella Attardi · 2017 · Cell Death and Differentiation
Links between mutant p53 and genomic instability
Hanel, Walter, Moll, Ute M. · 2012 · Journal of Cellular Biochemistry
p63 is a suppressor of tumorigenesis and metastasis interacting with mutant p53
Gerry Melino · 2011 · Cell Death and Differentiation
Modeling Familial Cancer with Induced Pluripotent Stem Cells
Dung‐Fang Lee, Jie Su, Huen Suk Kim, Betty Chang, Dmitri Papatsenko, Ruiying Zhao, Ye Yuan, Julian A. Gingold, Weiya Xia, Henia Darr et al. · 2015 · Cell
Ubiquitination and Degradation of Mutant p53
Lukashchuk, Natalia, Vousden, Karen H. · 2007 · Molecular and Cellular Biology
PI3K/Akt-mediated regulation of p53 in cancer
Aswin Abraham, Eric O’Neill · 2014 · Biochemical Society Transactions
A common gain of function of p53 cancer mutants in inducing genetic instability
De‐Pei Liu, Hoseok Song, Yang Xu · 2009 · Oncogene
A Genetic Progression Model of BrafV600E-Induced Intestinal Tumorigenesis Reveals Targets for Therapeutic Intervention
Roland Rad, Juan Cadiñanos, Lena Rad, Ignacio Varela, Alexander Strong, Lydia Kriegl, Fernando Constantino‐Casas, Stefan Eser, Maren Hieber, Barbara Seidler et al. · 2013 · Cancer Cell
Yes-Associated Protein Mediates Immune Reprogramming in Pancreatic Ductal Adenocarcinoma
S. Murakami, D. Shahbazian, R. Surana, Wei-Ying Zhang, Hengye Chen, G. Graham, Shannon M. White, L. Weiner, Chun-Ling Yi · 2016 · Oncogene
Tumour suppression by p53: the importance of apoptosis and cellular senescence
Valentina Zuckerman, Kamil Wolyniec, Ronit Vogt Sionov, Sue Haupt, Ygal Haupt · 2009 · The Journal of Pathology
Molecular biology of lung cancer: Clinical implications
Kwun Meng Fong, John Dorrance Minna · 2002 · Clinics in Chest Medicine
Transcription regulation by mutant p53
Lilach Weisz, Moshe Oren, Varda Rotter · 2007 · Oncogene
Chaperone-mediated autophagy degrades mutant p53
Helin Vakifahmetoglu-Norberg, Minsu Kim, Hongguang Xia, Marcin Iwanicki, Dimitry Ofengeim, Jonathan L. Coloff, Lifeng Pan, Tan A. Ince, Guido Kroemer, Joan S. Brugge et al. · 2013 · Genes & Development
Interplay between Notch1 and Notch3 promotes EMT and tumor initiation in squamous cell carcinoma
Mitsuteru Natsuizaka, Kelly A. Whelan, Shingo Kagawa, Koji Tanaka, Véronique Giroux, Prasanna Modayur Chandramouleeswaran, Apple Long, Varun Sahu, Douglas S. Darling, Jianwen Que et al. · 2017 · Nature Communications
Immunotherapy for pancreatic cancer — science driving clinical progress
Dan A. Laheru, Elizabeth M. Jaffee · 2005 · Nature reviews. Cancer
Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression
Gianluca Bossi, Eleonora Lapi, Sabrina Strano, Cinzia Rinaldo, Giovanni Blandino, Ada Sacchi · 2005 · Oncogene
How important are post-translational modifications in p53 for selectivity in target-gene transcription and tumour suppression?
A Olsson, Claudia Manzl, Andreas Strasser, Andreas Villunger · 2007 · Cell Death and Differentiation
Mutant p53 Enhances Nuclear Factor κB Activation by Tumor Necrosis Factor α in Cancer Cells
Lilach Weisz, Alexander Damalas, Michalis Liontos, Panagiotis Karakaidos, Giulia Fontemaggi, Revital Maor-Aloni, Marina Lifshitc Kalis, Massimo Levrero, Sabrina Strano, Vassilis G. Gorgoulis et al. · 2007 · Cancer Research
Mutant p53: it’s not all one and the same
Margaret C. Kennedy, Scott W. Lowe · 2022 · Cell Death and Differentiation
Translating p53-based therapies for cancer into the clinic
Sylvain Peuget, Xiaolei Zhou, Galina Selivanova · 2024 · Nature reviews. Cancer
20 years studying p53 functions in genetically engineered mice
Lawrence A. Donehower, Guillermina Lozano · 2009 · Nature reviews. Cancer
YAP enhances the pro‐proliferative transcriptional activity of mutant p53 proteins
Silvia Di Agostino, Giovanni Sorrentino, Eleonora Ingallina, Fabio Valenti, Maria A. Ferraiuolo, Silvio Bicciato, Silvano Piazza, Sabrina Strano, Giannino Del Sal, Giovanni Blandino · 2015 · EMBO Reports
Mutant p53 enhances MET trafficking and signalling to drive cell scattering and invasion
Patricia A. J. Muller, Antonio G. Trinidad, Paul Timpson, Jennifer P. Morton, Sara R. Zanivan, Peter V. E. van den Berghe, Colin Nixon, Saadia A. Karim, Patrick T. Caswell, Jacqueline E. Noll et al. · 2012 · Oncogene
Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study
Ken H. Young, Karen Leroy, Michael Boe Møller, Gisele W. B. Colleoni, Margarita Sánchez‐Beato, Fabio Rodrigues Kerbauy, Corinne Haïoun, Jens C. Eickhoff, Allen H. Young, Philippe Gaulard et al. · 2008 · Blood
p53 Isoforms: Key Regulators of the Cell Fate Decision
Sebastien M. Joruiz, Jean‐Christophe Bourdon · 2016 · Cold Spring Harbor Perspectives in Medicine
Metastatic pancreatic cancer is dependent on oncogenic Kras in mice
Collins, Meredith A., Brisset, Jean-Christophe, Zhang, Yaqing, Bednar, Filip, Pierre, Josette, Heist, Kevin A., Galbán, Craig J., Galbán, Stefanie, di Magliano, Marina Pasca · 2012 · PLoS ONE
Mutant p53 Gain-of-Function: Role in Cancer Development, Progression, and Therapeutic Approaches
Eduardo Alvarado-Ortiz, Karen Griselda de la Cruz-López, Jared Becerril-Rico, Miguel Ángel Sarabia-Sánchez, Elizabeth Ortíz-Sánchez, Alejandro M. García-Carrancá · 2021 · Frontiers in Cell and Developmental Biology
Chaperone-dependent stabilization and degradation of p53 mutants
Petr Müller, Roman Hrstka, David Coomber, David Philip Lane, Bořivoj Vojtěšek · 2008 · Oncogene
Non-germline genetically engineered mouse models for translational cancer research
Joerg Heyer, Lawrence N. Kwong, Scott W. Lowe, Lynda Chin · 2010 · Nature reviews. Cancer
Mutant p53 reactivation by small molecules makes its way to the clinic
Vladimir J.N. Bykov, Klas G. Wiman · 2014 · FEBS Letters
p53 and NF‐κB: different strategies for responding to stress lead to a functional antagonism
Prashanth Ak, Arnold J. Levine · 2010 · The FASEB Journal
Metabolic Regulation of Apoptosis in Cancer
Kenkyo Matsuura, Kaleigh Canfield, William W. Feng, Manabu Kurokawa · 2016 · International review of cytology
Mutant p53 mediates survival of breast cancer cells
L Y Lim, Nick Vidnovic, Leif William Ellisen, C-O Leong · 2009 · British Journal of Cancer
Are interactions with p63 and p73 involved in mutant p53 gain of oncogenic function?
Y Li, Carol L. Prives · 2007 · Oncogene
The regulation of MDM2 oncogene and its impact on human cancers
Yuhan Zhao, Haiyang Yu, Wenwei Hu · 2014 · Acta Biochimica et Biophysica Sinica
Zebrafish Models for Cancer
Shu Liu, Steven D. Leach · 2011 · Annual Review of Pathology Mechanisms of Disease
Transformation of Human and Murine Fibroblasts without Viral Oncoproteins
Jesse S. Boehm, Meghan T. Hession, Sara E. Bulmer, William C. Hahn · 2005 · Molecular and Cellular Biology
BH3-only proteins in cell death initiation, malignant disease and anticancer therapy
Verena Labi, Miriam Erlacher, Stephan Kießling, Andreas Villunger · 2006 · Cell Death and Differentiation
Notch signaling contributes to the pathogenesis of human osteosarcomas
Feyza Engin, Terry Bertin, O. Ma, Ming‐Ming Jiang, Lingling Wang, Richard E. Sutton, Lawrence A. Donehower, Brendan Lee · 2009 · Human Molecular Genetics
Germline Brca2 Heterozygosity Promotes Kras -Driven Carcinogenesis in a Murine Model of Familial Pancreatic Cancer
Ferdinandos Skoulidis, Liam D. Cassidy, Venkat Pisupati, Jon Gunnlaugur Jonasson, Hörður Bjarnason, Jorunn Erla Eyfjord, Florian A. Karreth, Michael Lim, Lorraine M. Barber, Susan A. Clatworthy et al. · 2010 · Cancer Cell
Mouse models of pancreatic cancer.
M. Herreros-Villanueva, E. Hijona, Á. Cosme, L. Bujanda · 2012 · World Journal of Gastroenterology
A Multiscale Map of the Stem Cell State in Pancreatic Adenocarcinoma
Nikki K. Lytle, Lesley Paige Ferguson, Nirakar Rajbhandari, Kathryn L. Gilroy, Raymond G. Fox, Anagha J. Deshpande, Christian M. Schürch, Michael Hamilton, Neil Robertson, Wei Lin et al. · 2019 · Cell
Current understanding of the role and targeting of tumor suppressor p53 in glioblastoma multiforme
England, Bryant, Huang, Tiangui, Karsy, Michael · 2013 · Tumor Biology
Reactive Oxygen Species Induced p53 Activation: DNA Damage, Redox Signaling, or Both?
Tao Shi, Tobias B. Dansen · 2020 · Antioxidants and Redox Signaling
Altered RNA Splicing by Mutant p53 Activates Oncogenic RAS Signaling in Pancreatic Cancer
Luisa F. Escobar‐Hoyos, Alex Penson, Ram Kannan, Hana Cho, Chun‐Hao Pan, Rohit Kumar Singh, Lisa Helene Apken, G. Aaron Hobbs, Renhe Luo, Nicolas Lecomte et al. · 2020 · Cancer Cell
Gain-of-Function Mutant p53: All the Roads Lead to Tumorigenesis
Yan Stein, Varda Rotter, Ronit Aloni-Grinstein · 2019 · International Journal of Molecular Sciences
Single-cell multi-omics identifies chronic inflammation as a driver of TP53-mutant leukemic evolution
Rodriguez-Meira, Alba, Norfo, Ruggiero, Wen, Sean, Chédeville, Agathe L., Rahman, Haseeb, O’Sullivan, Jennifer, Wang, Guanlin, Louka, Eleni, Kretzschmar, Warren W., Paterson, Aimee et al. · 2023 · Nature Genetics
Oncogenic KRAS Recruits an Expansive Transcriptional Network through Mutant p53 to Drive Pancreatic Cancer Metastasis
Michael P. Kim, Xinqun Li, Jenying Deng, Yun Zhang, Bingbing Dai, Kendra L. Allton, Tara G. Hughes, Christian Siangco, Jithesh Jose Augustine, Ya’an Kang et al. · 2021 · Cancer Discovery
The role of tumor suppressor p53 in the antioxidant defense and metabolism
Budanov, Andrei V. · 2014 · Subcellular Biochemistry
Current developments of targeting the p53 signaling pathway for cancer treatment
Jing Li Huang · 2020 · Pharmacology & Therapeutics
Germline loss of PKM2 promotes metabolic distress and hepatocellular carcinoma
Talya L. Dayton, Vasilena Gocheva, Kathryn M. Miller, William J. Israelsen, Arjun J. Bhutkar, Clary B. Clish, Shawn M. Davidson, Alba Luengo, Roderick Terry Bronson, Tyler Jacks et al. · 2016 · Genes & Development
Should mutant TP53 be targeted for cancer therapy?
Zilu Wang, Andreas Strasser, Gemma L. Kelly · 2022 · Cell Death and Differentiation
Mutant p53 facilitates somatic cell reprogramming and augments the malignant potential of reprogrammed cells
Rachel Sarig, Noa Rivlin, Ran Brosh, Chamutal Bornstein, Iris Kamer, Osnat Ezra, Alina Molchadsky, Naomi Goldfinger, Ori Jacob Brenner, Varda Rotter · 2010 · The Journal of Experimental Medicine
Mutant p53 on the Path to Metastasis
Qiaosi Tang, Zhenyi Su, Wei Gu, Anil K. Rustgi · 2019 · Trends in cancer
Osteosarcoma: Molecular Pathogenesis and iPSC Modeling
Lin, Yu-Hsuan, Jewell, Brittany E., Gingold, Julian, Lu, Linchao, Zhao, Ruiying, Wang, Lisa L., Lee, Dung-Fang · 2017 · Trends in Molecular Medicine